article thumbnail

Attorney Tope Leyimu Discusses Proposed FDA ban on Hair Relaxer Products Containing Harmful Chemicals – Xtalks Life Science Podcast Ep. 137

XTalks

This episode features an interview with Attorney Temitope (Tope) Leyimu, a toxic exposure attorney at Motley Rice who is leading a lawsuit over hair relaxing products that contain harmful chemicals. The FDA recently issued a recommendation for the recall of chemical hair relaxers containing harmful chemicals.

article thumbnail

Top Life Science News and Trends in 2023 at Xtalks

XTalks

In 2023, there were significant advancements and notable trends in the life sciences. Xtalks compiled a list of its top life science news and trends of 2023, which provided readers with the latest developments, information and expert insights across life science industries, including pharma, biotech and medical device.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How AI/ML-based PHI & PII redaction solutions can help life sciences organizations

Cloudbyz

In today’s digital age, life sciences organizations are collecting, storing, and processing vast amounts of sensitive data, including personally identifiable information (PII) and protected health information (PHI). As such, it’s becoming increasingly challenging for organizations to manage and secure this data.

article thumbnail

Key findings from life sciences digital pathology adoption survey 

Drug Discovery World

Nearly three-fourths of life sciences organisations surveyed have invested in digital pathology to advance drug research and development (R&D), according to new research commissioned by Proscia. The post Key findings from life sciences digital pathology adoption survey appeared first on Drug Discovery World (DDW).

article thumbnail

NYC Life Sciences Sector Poised for High-Growth Phase

BioSpace

population but contains 10% of all U.S. According to a recent report, the New York City Metro area is home to 7% of the U.S. biochemists and biophysicists and 12% of U.S. chemists.

article thumbnail

Streamlining development with containment in early drug discovery

Drug Discovery World

It may seem counterintuitive to spend time and money on planning for containment and delivery systems for a drug in the earliest stages of discovery when the chances of that molecule making it to market are still quite low. But waiting too long to assess containment and delivery carries its own risks. Testing compatibility.

article thumbnail

XBB.1.5 Omicron Subvariant + FDA Approves AstraZeneca’s New Asthma Inhaler – Xtalks Life Science Podcast Ep. 93

XTalks

Ayesha also talked about the FDA approval of AstraZeneca’s asthma inhaler Airsupra, the first-in-class drug that contains both a beta agonist and corticosteroid. Subscribe to the Xtalks Life Science Podcast to never miss a new episode. Hear more about the new subvariant and why scientists are keeping a close eye on it.